Cargando…

Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study

Multiple sclerosis (MS) is a chronic and demyelinating disease with an autoimmune origin, which leads to neurodegeneration and progressive disability. Approximately 30 to 50% of patients do not respond optimally to disease-modifying therapies (DMTs), and therapeutic response may be influenced by gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Gomez-Gaitan, Esteban Alejandro, Garcia-Ortega, Yessica Eleanet, Saldaña-Cruz, Ana Miriam, Contreras-Haro, Betsabe, Gamez-Nava, Jorge Ivan, Perez-Guerrero, Emilio Edsaul, Nava-Valdivia, Cesar Arturo, Gallardo-Moya, Sergio, Martinez-Hernandez, Alejandra, Gonzalez Lopez, Laura, Rios-Gonzalez, Blanca Esthela, Marquez-Pedroza, Jazmin, Mendez-del Villar, Miriam, Esparza-Guerrero, Yussef, Villagomez-Vega, Alejandra, Macias Islas, Miguel Angel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572793/
https://www.ncbi.nlm.nih.gov/pubmed/37834042
http://dx.doi.org/10.3390/ijms241914594
_version_ 1785120315402092544
author Gomez-Gaitan, Esteban Alejandro
Garcia-Ortega, Yessica Eleanet
Saldaña-Cruz, Ana Miriam
Contreras-Haro, Betsabe
Gamez-Nava, Jorge Ivan
Perez-Guerrero, Emilio Edsaul
Nava-Valdivia, Cesar Arturo
Gallardo-Moya, Sergio
Martinez-Hernandez, Alejandra
Gonzalez Lopez, Laura
Rios-Gonzalez, Blanca Esthela
Marquez-Pedroza, Jazmin
Mendez-del Villar, Miriam
Esparza-Guerrero, Yussef
Villagomez-Vega, Alejandra
Macias Islas, Miguel Angel
author_facet Gomez-Gaitan, Esteban Alejandro
Garcia-Ortega, Yessica Eleanet
Saldaña-Cruz, Ana Miriam
Contreras-Haro, Betsabe
Gamez-Nava, Jorge Ivan
Perez-Guerrero, Emilio Edsaul
Nava-Valdivia, Cesar Arturo
Gallardo-Moya, Sergio
Martinez-Hernandez, Alejandra
Gonzalez Lopez, Laura
Rios-Gonzalez, Blanca Esthela
Marquez-Pedroza, Jazmin
Mendez-del Villar, Miriam
Esparza-Guerrero, Yussef
Villagomez-Vega, Alejandra
Macias Islas, Miguel Angel
author_sort Gomez-Gaitan, Esteban Alejandro
collection PubMed
description Multiple sclerosis (MS) is a chronic and demyelinating disease with an autoimmune origin, which leads to neurodegeneration and progressive disability. Approximately 30 to 50% of patients do not respond optimally to disease-modifying therapies (DMTs), and therapeutic response may be influenced by genetic factors such as genetic variants. Therefore, our study aimed to investigate the association of the HLA-DRB1*0403 genetic variant and therapeutic response to DMTs in MS. We included 105 patients with MS diagnosis. No evidence of disease activity based on the absence of clinical relapse, disability progression or radiological activity (NEDA-3) was used to classify the therapeutic response. Patients were classified as follows: (a) controls: patients who achieved NEDA-3; (b) cases: patients who did not achieve NEDA-3. DNA was extracted from peripheral blood leukocytes. HLA-DRB1*0403 genetic variant was analyzed by quantitative polymerase chain reaction (qPCR) using TaqMan probes. NEDA-3 was achieved in 86.7% of MS patients treated with DMTs. Genotype frequencies were GG 50.5%, GA 34.3%, and AA 15.2%. No differences were observed in the genetic variant AA between patients who achieved NEDA-3 versus patients who did not achieve NEDA-3 (48.7% vs. 43.1%, p = 0.6). We concluded that in Mexican patients with MS, HLA-DRB1*0403 was not associated with the therapeutic response to DMTs.
format Online
Article
Text
id pubmed-10572793
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105727932023-10-14 Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study Gomez-Gaitan, Esteban Alejandro Garcia-Ortega, Yessica Eleanet Saldaña-Cruz, Ana Miriam Contreras-Haro, Betsabe Gamez-Nava, Jorge Ivan Perez-Guerrero, Emilio Edsaul Nava-Valdivia, Cesar Arturo Gallardo-Moya, Sergio Martinez-Hernandez, Alejandra Gonzalez Lopez, Laura Rios-Gonzalez, Blanca Esthela Marquez-Pedroza, Jazmin Mendez-del Villar, Miriam Esparza-Guerrero, Yussef Villagomez-Vega, Alejandra Macias Islas, Miguel Angel Int J Mol Sci Article Multiple sclerosis (MS) is a chronic and demyelinating disease with an autoimmune origin, which leads to neurodegeneration and progressive disability. Approximately 30 to 50% of patients do not respond optimally to disease-modifying therapies (DMTs), and therapeutic response may be influenced by genetic factors such as genetic variants. Therefore, our study aimed to investigate the association of the HLA-DRB1*0403 genetic variant and therapeutic response to DMTs in MS. We included 105 patients with MS diagnosis. No evidence of disease activity based on the absence of clinical relapse, disability progression or radiological activity (NEDA-3) was used to classify the therapeutic response. Patients were classified as follows: (a) controls: patients who achieved NEDA-3; (b) cases: patients who did not achieve NEDA-3. DNA was extracted from peripheral blood leukocytes. HLA-DRB1*0403 genetic variant was analyzed by quantitative polymerase chain reaction (qPCR) using TaqMan probes. NEDA-3 was achieved in 86.7% of MS patients treated with DMTs. Genotype frequencies were GG 50.5%, GA 34.3%, and AA 15.2%. No differences were observed in the genetic variant AA between patients who achieved NEDA-3 versus patients who did not achieve NEDA-3 (48.7% vs. 43.1%, p = 0.6). We concluded that in Mexican patients with MS, HLA-DRB1*0403 was not associated with the therapeutic response to DMTs. MDPI 2023-09-27 /pmc/articles/PMC10572793/ /pubmed/37834042 http://dx.doi.org/10.3390/ijms241914594 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Gomez-Gaitan, Esteban Alejandro
Garcia-Ortega, Yessica Eleanet
Saldaña-Cruz, Ana Miriam
Contreras-Haro, Betsabe
Gamez-Nava, Jorge Ivan
Perez-Guerrero, Emilio Edsaul
Nava-Valdivia, Cesar Arturo
Gallardo-Moya, Sergio
Martinez-Hernandez, Alejandra
Gonzalez Lopez, Laura
Rios-Gonzalez, Blanca Esthela
Marquez-Pedroza, Jazmin
Mendez-del Villar, Miriam
Esparza-Guerrero, Yussef
Villagomez-Vega, Alejandra
Macias Islas, Miguel Angel
Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study
title Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study
title_full Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study
title_fullStr Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study
title_full_unstemmed Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study
title_short Genetic Variant HLA-DRB1*0403 and Therapeutic Response to Disease-Modifying Therapies in Multiple Sclerosis: A Case-Control Study
title_sort genetic variant hla-drb1*0403 and therapeutic response to disease-modifying therapies in multiple sclerosis: a case-control study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572793/
https://www.ncbi.nlm.nih.gov/pubmed/37834042
http://dx.doi.org/10.3390/ijms241914594
work_keys_str_mv AT gomezgaitanestebanalejandro geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy
AT garciaortegayessicaeleanet geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy
AT saldanacruzanamiriam geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy
AT contrerasharobetsabe geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy
AT gameznavajorgeivan geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy
AT perezguerreroemilioedsaul geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy
AT navavaldiviacesararturo geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy
AT gallardomoyasergio geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy
AT martinezhernandezalejandra geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy
AT gonzalezlopezlaura geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy
AT riosgonzalezblancaesthela geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy
AT marquezpedrozajazmin geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy
AT mendezdelvillarmiriam geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy
AT esparzaguerreroyussef geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy
AT villagomezvegaalejandra geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy
AT maciasislasmiguelangel geneticvarianthladrb10403andtherapeuticresponsetodiseasemodifyingtherapiesinmultiplesclerosisacasecontrolstudy